We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

By LabMedica International staff writers
Posted on 01 Sep 2015
Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that can act on lipids in the cell membrane.

PTEN, which is missing in 60% to 70% of metastatic cancers in humans, is the name of a phospholipid phosphatase protein, and gene that encodes it. More...
The PTEN gene acts as a tumor suppressor gene thanks to the role of its protein product in regulation of the cycle of cell division, preventing cells from growing and dividing too rapidly.

Due to difficulties in crystallizing the PTEN dimer, investigators at Carnegie Mellon University (Pittsburgh, PA, USA) and a group of international collaborators used an advanced small-angle X-ray scattering (SAXS) technique to establish its structure in aqueous solution.

They reported in the August 20, 2015, online edition of the journal Structure that PTEN formed homodimers in vitro. To be fully functional, the C-terminal tails of the two proteins comprising the PTEN dimers had to bind the protein bodies in a cross-wise fashion, which made them more stable. As a result, they could more efficiently interact with the cell membrane, regulate cell growth, and suppress tumor formation.

Phosphorylation of the unstructured C-terminal tail of PTEN reduced PTEN activity, and this result was interpreted as a blockage of the PTEN membrane binding interface through this tail. The results presented in this paper instead suggested that the C-terminal tail functioned in stabilizing the homodimer, and that tail phosphorylation interfered with this stabilization.

"Membrane-incorporated and membrane-associated proteins like PTEN make up one-third of all proteins in our body. Many important functions in health and disease depend on their proper functioning," said senior author Dr. Mathias Lösche, professor of physics and of biomedical engineering at Carnegie Mellon University. "Despite PTEN's importance in human physiology and disease, there is a critical lack of understanding of the complex mechanisms that govern its activity."

Related Links:

Carnegie Mellon University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.